表紙
市場調査レポート

腫瘍崩壊症候群:世界の治験レビュー

Tumor Lysis Syndrome Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 305097
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
腫瘍崩壊症候群:世界の治験レビュー Tumor Lysis Syndrome Global Clinical Trials Review, H1, 2014
出版日: 2014年05月30日 ページ情報: 英文 74 Pages
概要

当レポートでは、腫瘍崩壊症候群に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 腫瘍崩壊症候群
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の上位国
    • 欧州の上位5ヶ国
    • 北米の上位国
    • 中東・アフリカの主要国
    • 中南米の上位国

G7諸国での治験件数:代謝性疾患の治験全体における腫瘍崩壊症候群の割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:代謝性疾患の治験全体における腫瘍崩壊症候群の割合

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 腫瘍崩壊症候群治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Sanofi
    • 武田薬品工業
    • A. Menarini Industrie Farmaceutiche Riunite Srl
  • 代表的な研究機関・病院の治験の概要
    • The University of Texas M. D. Anderson Cancer Center
    • 福井大学

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2180CTIDB

GlobalData's clinical trial report, "Tumor Lysis Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Tumor Lysis Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tumor Lysis Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tumor Lysis Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Tumor Lysis Syndrome
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Tumor Lysis Syndrome to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Tumor Lysis Syndrome to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Tumor Lysis Syndrome
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Tumor Lysis Syndrome Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • Takeda Pharmaceutical Company Limited
      • Clinical Trial Overview of Takeda Pharmaceutical Company Limited
      • A. Menarini Industrie Farmaceutiche Riunite Srl
      • Clinical Trial Overview of A. Menarini Industrie Farmaceutiche Riunite Srl
    • Clinical Trial Overview of Top Institutes / Government
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • University of Fukui
      • Clinical Trial Overview of University of Fukui
    • Five Key Clinical Profiles
    • Appendix
      • Abbreviations
      • Definitions
      • Research Methodology
      • Secondary Research
      • About GlobalData
      • Contact Us
      • Disclaimer
      • Source

List of Tables

  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials by Region, 2014*
  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Tumor Lysis Syndrome to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Tumor Lysis Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Tumor Lysis Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Tumor Lysis Syndrome to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Tumor Lysis Syndrome Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Tumor Lysis Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by A. Menarini Industrie Farmaceutiche Riunite Srl, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Fukui, 2014*

List of Figures

  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Proportion of Tumor Lysis Syndrome to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Tumor Lysis Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Tumor Lysis Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Tumor Lysis Syndrome to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Tumor Lysis Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Tumor Lysis Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Tumor Lysis Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top